VENTRITEX PATENT CROSS-LICENSING AGREEMENTS WITH CPI, TELECTRONICS
This article was originally published in The Gray Sheet
Executive Summary
VENTRITEX PATENT CROSS-LICENSING AGREEMENTS WITH CPI, TELECTRONICS for implantable defibrillators will result in Ventritex recognizing a charge of about $19 mil. for the fourth quarter ended June 30, the firm says in a July 27 press release announcing the agreements. The charge includes one-time payments to Lilly subsidiary Cardiac Pacemakers, Inc. and Telectronics, "as well as other related settlement expenses." In addition to the one-time payments to both firms, Ventritex will pay royalties to CPI on sales of products incorporating the licensed patents. Ventritex markets the Cadence third-generation implantable pacemaker- cardioverter-defibrillator, which was launched in the spring ("The Gray Sheet" May 10, p. 3). The Cadence is the Sunnyvale, California firm's first commercially marketed product. Frank Fischer, president and CEO, said the two recent agreements will provide "expanded design freedom for future products." Specific terms of the agreements were not disclosed. The licensing agreements resolve a pending patent infringement case between Ventritex and Telectronics and threatened litigation with CPI. Ventritex and CPI have been involved in patent-related discussions for the last several months; according to CPI, the licensing agreement "settled all outstanding patent issues." In May 1992, Ventritex entered into a cross-licensing agreement with Medtronic covering patents for devices used to treat tachyarrhythmias ("The Gray Sheet" Sept. 14, 1992, p. 4). That agreement, like the one with CPI, includes royalty payments. As a result of the recent licensing agreements, Intermedics is the only remaining implantable defibrillator firm with which Ventritex has pending patent infringement litigation. Earlier this month, a U.S. District Judge for the Northern District of California dismissed an action filed by Ventritex "seeking a declaration that seven of Intermedics' patents were invalid or not infringed by Ventritex' Cadence" device, according to Intermedics. A motion to file a supplemental complaint was denied. Intermedics filed an amended complaint against Ventritex alleging infringement of nine patents in May ("The Gray Sheet" May 10, p. 3). The case is pending in the U.S. District Court for the Southern District of Texas in Galveston, Texas.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.